Rx&D Welcomes its Newest Member: Proteocyte Diagnostics Inc.

OTTAWA, Nov. 8, 2011 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) President Russell Williams is pleased to announce today the addition of Proteocyte Diagnostics Inc. as a new biopharmaceutical member to the association representing the innovative pharmaceutical industry in Canada.

Proteocyte Diagnostics Inc. (www.proteocyte.com) is an early stage molecular diagnostics company founded by Dr. Paul Walfish and York Medtech Partners Inc. Proteocyte Diagnostics is developing a diagnostic platform to provide highly accurate prognostic assessment of cancers in individual patients.

The management team led by Dr. Ken Pritzker, President & CEO, has extensive experience in bringing innovative cancer diagnostics to clinical practice.

"Rx&D is a community of industry colleagues that are focused on innovation and that live by a well-established Code of Ethical Practices and Transparency Guidelines," said Dr. Pritzker. "Membership in Rx&D allows us to work more collaboratively in developing health care solutions for Canadians."

"More and more companies are recognizing the value and benefits of becoming a member of Rx&D. We are pleased to welcome Proteocyte into our association as they bring their distinctive expertise which gives us a broader foundation, making the research-based pharmaceutical industry stronger," said Rx&D President Russell Williams.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community represents 15,000 men and women working for 50 member companies and invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX

For further information:

Christine Choury,
Media Relations
Telephone: 613-236-0455
E-mail: cchoury@canadapharma.org

Profil de l'entreprise

CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.